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OBJECTIVES: The purpose of this study was to evaluate the relationship between the serum levels of calcitonin
gene-related peptide (CGRP) and the prognosis of pediatric patients with severe pneumonia.
METHODS: Children diagnosed with severe pneumonia (n=76) were stratified into the survival (n=58) and non-
survival groups (n=18) according to their 28-day survival status and into the non-risk (n=51), risk (n=17) and
high-risk (n=8) categories based on the pediatric critical illness score (PCIS). Demographic data and laboratory
results were collected. Serum CGRP levels were determined by enzyme-linked immunosorbent assay (ELISA).
A receiver operating characteristic (ROC) curve was generated to determine the cutoff score for high CGRP levels.
RESULTS: Serum CGRP levels were significantly higher in the survival group than in the non-survival group and
were significantly higher in the non-risk group than in the risk and high-risk groups. The ROC curve for the
prognostic potential of CGRP yielded a significant area under the curve (AUC) value with considerable sensitivity
and specificity.
CONCLUSION: Our findings show that CGRP downregulation might be a diagnostic marker that predicts the
prognosis and survival of children with severe pneumonia.
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’ INTRODUCTION
Respiratory tract infections play an important role in
pediatric diseases, result in serious illness, and have a high
incidence rate (1). In recent years, with continuous improve-
ments in living conditions, health care awareness, and
medical and health conditions, the incidence of infectious
diseases in infants and young children continues to decline.
Respiratory infection is still the most common disease in
children (2). Pneumonia remains the leading cause of death
among children in China. Children are more prone to
infectious respiratory diseases because of the anatomical
and physiological characteristics of the respiratory system in
early childhood. Respiratory infection causes mucus obstruc-
tion, leading to interstitial pneumonia, emphysema, atelectasis
and so on (3). Pneumonia refers to inflammation in the final
airway, alveoli and interstitium of the lungs caused by
pathogenic microorganisms, physical and chemical factors,
immune injury, allergy and antibiotics (4). It is a common
infectious disease that seriously threatens human health.
Patients with severe pneumonia may suffer from related
clinical symptoms involving the circulatory, nervous and
digestive tract systems. Early diagnosis and treatment can
reduce mortality; therefore, an appropriate biomarker would
be helpful for diagnosis and to guide treatment.
Calcitonin gene-related peptide (CGRP), a sensory neuro-
peptide composed of 37 amino acids, is a novel member of
the calcitonin family of peptides that includes adrenome-
dullin, islet amyloid polypeptides (IAPPs), calcitonin, and
calcitonin receptor-stimulating peptides (CRSPs) (5). CGRP,
which is encoded by the same gene that encodes calcitonin,
was first discovered in humans and other mammals by
Amara et al. in 1982 (6). CGRP was recently shown to be
widely distributed in the nervous system, cardiovascular
system and lungs (7). In recent years, numerous studies have
provided strong evidence that CGRP possesses many
biological activities, including in neuronal regeneration,
endothelium-dependent vasodilation, the inhibition of vas-
cular smooth muscle proliferation, and bone growth (8,9).
In addition, other studies have indicated that CGRP may beDOI: 10.6061/clinics/2020/e1448
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involved in the pathophysiology of pulmonary diseases.
A large body of evidence indicates that CGRP protects
alveolar epithelial type II cells against hyperoxia-induced
oxidative stress injury, DNA damage and apoptosis (10,11).
Moreover, Norton et al. reported that CGRP hyperpolarizes
pulmonary artery endothelial cells and smooth muscle
cells (SMCs) via the activation of ATP-sensitive K+ (KATP)
channels (12). Augustyniak et al. discovered that CGRP sig-
nificantly suppresses M. catarrhalis-triggered alveolar epithe-
lial type II cell apoptosis and neutrophil degranulation (13).
However, the expression levels of CGRP and its relationship
with prognosis in severe childhood pneumonia have not
previously been examined.
’ MATERIALS AND METHODS
Patients
A total of 76 sequential children agedo3 years, diagnosed
with severe pneumonia and hospitalized at our department
between December 2013 and June 2017 were included in this
study. The inclusion criteria based on the diagnostic criteria
for severe childhood pneumonia were as follows: chest wall
depression and severe respiratory distress; subjective symp-
toms of central cyanosis, apastia, dehydration and dimin-
ished consciousness; and the progression of hypoxemia and
intrapulmonary and extrapulmonary complications. Patients
with malignant tumors, malnutrition, autoimmune diseases,
or severe heart, liver or kidney failure were excluded. All
patients were initially divided into a survival group (n=58)
and a non-survival group (n=18) according to their 28-day
survival status. Their pediatric critical illness score (PCIS)
was determined by two attending physicians independently
within 24 hours after admission, and the results were
averaged. The total possible score is 100 points, and the
severity of pneumonia is ranked as follows: 480 points,
noncritical; 71–80 points, critical; and p70 points, extremely
critical. We then classified the patients into three subgroups
based on the PCIS: non-risk (PCIS480, n=51), risk
(70oPCISp80, n=17) and high risk (PCISp70, n=8). The
present study was approved by the Ethics Committee of
Xiamen Chang Gung Hospital.
Laboratory tests and clinical data
Demographic information, such as age, sex and the PCIS,
was obtained within 24 hours of admission. Routine blood
tests, including white blood cell (WBC) counts, were
performed using an automatic biochemical analyzer (Beck-
man Coulter, Inc., Brea, CA, USA).
Measurement of serum CGRP
Peripheral venous blood was drawn after admission and
collected in plastic tubes containing ethylenediaminetetraa-
cetic acid (EDTA) as an anticoagulant plus aprotinin (500
KIU/mL blood; Trasylol, Bayer, Leverkusen, Germany).
Serum samples were isolated by centrifugation at 3000 rpm
for 10 minutes and stored at -20oC. Serum CGRP levels were
measured by enzyme-linked immunosorbent assay (ELISA)
using a commercial ELISA kit (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s protocol. The
absorbance at 450 nm was measured using a microplate reader.
Statistical analysis
All data are expressed as the mean ± standard devia-
tion (SD). Statistical analysis was performed using SPSS
version 22.0 (SPSS Inc., Chicago, IL, USA). Differences
between groups were analyzed using Student’s t-test.
Receiver operating characteristic (ROC) curves were con-
structed using XLSTAT software. po0.05 was considered to
indicate statistical significance.
’ RESULTS
CGRP was highly expressed in the survival group
Seventy-six patients with severe pneumonia were hospi-
talized during the study period. These patients had a mean
age of 18.3±9.8 months (range, 1 to 36 months) and included
42 (55.2%) males and 34 (44.7%) females. After 28 days,
the survival rate was 76.31% (58 patients). A comparison of
the clinical characteristics of the survival (n=58) and non-
survival (n=18) groups revealed no differences in sex, age,
PCIS or WBC count (Table 1, p40.05). Compared with the
non-survival group, the survival group had significantly
increased serum levels of CGRP (Figure 1, po0.05).
CGRP was significantly increased in non-risk
patients
After categorizing the patients into the 3 risk groups
according to the PCIS, there were 51 patients (females/
males, 28/23) in the non-risk group, 17 (females/males, 9/8)
in the risk group, and 8 (females/males, 5/3) in the high-risk
group. The average age was 18.4 months in the non-risk
group, 19.1 months in the risk group, and 15.9 months in the
Figure 1 - Serum CGRP levels in survival group (n=58) and non-
survival group (n=18) determined by ELISA.
Table 1 - Comparison of demographic data between the survival and non-survival groups (mean±SD).
Group Cases Females/Males Age (months) PCIS WBC count (109/L)
Survival 58 32/26 19.1±10.3 80.49±6.53 12.14±2.36
Non-survival 18 10/8 15.9±7.8 81.50±7.60 11.97±1.63
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high-risk group (Table 2). The serum levels of CGRP in
each risk group were further studied. Serum CGRP levels
were markedly decreased in the risk and high-risk groups
compared with the non-risk group (all po0.05) and were
similar in the risk and high-risk groups (p40.05) (Figure 2).
Furthermore, ROC curves were generated to verify the
diagnostic role of serum CGRP, which yielded an area under
the curve (AUC) of 0.763 (95%CI: 0.658-0.868), a sensitivity of
84.5%, and a specificity of 72.2% at the optimal cutoff value
of 30 ng/L (Figure 3).
’ DISCUSSION
Severe pneumonia, the leading cause of mortality in
children under 5 years old, is characterized by hypoxemia,
central cyanosis, severe respiratory distress, diminished
consciousness, apastia and dehydration (14). Recently, a
few prognostic biomarkers that appear after the onset of
severe pneumonia have been reported. For example, Lee et al.
conducted a retrospective study of 152 adult patients with
severe pneumonia, including community-acquired pneumo-
nia (CAP), health care-associated pneumonia (HCAP), and
hospital-acquired pneumonia (HAP), and found a significant
correlation between elevated cardiac troponin (cTn) levels and
mortality (15). Yang et al. showed that decreased serum YKL-
40 levels after 5 days of standard therapy were an independent
risk factor for viral pneumonia in children diagnosed with
CAP (16). At present, we commonly use the PCIS to evaluate
the initial condition of critically ill children upon admission to
the pediatric intensive care unit (PICU) (17); however, whether
this score can determine the prognosis remains controversial.
Therefore, it is important to identify meaningful prognostic
indicators of severe pneumonia at the early stage.
Table 2 - Comparison of sex and age among the non-risk, risk
and high-risk groups.
Group Cases Females/Males Age (months)
non-risk 51 28/23 18.4±9.5
risk 17 9/8 19.1±11.1
high-risk 8 5/3 15.9±9.4
Figure 2 - Serum CGRP levels in children with non risk, risk and
high risk of severe pneumonia.
Figure 3 - ROC curve for serum CGRP exhibiting the prognostic potential of CGRP in severe childhood pneumonia.
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Cardioprotective and neuroprotective actions of CGRP
upregulation have been suggested. For instance, Guo et al.
stated that CGRP effectively reversed the hypoxia/reoxy-
genation (H/R)-induced reduction in mitochondrial mem-
brane potential and suppressed cytosolic reactive oxygen
species (ROS) and myocardial apoptosis (18). Furthermore,
Singh and colleagues reported that the exogenous adminis-
tration of CGRP suppressed macrophage infiltration and
inflammatory cytokine secretion, which attenuated Alzhei-
mer’s disease (AD), suggesting that CGRP is a potential
candidate target for the treatment of AD (19). CGRP has also
been implicated in the regulation of inflammation, prolifera-
tion and fibrosis in pulmonary diseases such as pulmonary
arterial hypertension (PAH), asthma, acute lung injury (ALI)
and pulmonary fibrosis (20-23). However, its prognostic
value in severe pneumonia is poorly understood. Our study
first showed that serum CGRP levels are associated with
mortality in patients with severe pneumonia after adjusting
for age, sex, PCIS and WBC count at admission, suggesting
that CGRP may be a novel risk factor for mortality in
children with severe pneumonia. According to our results,
assessing serum CGRP levels in children with severe pneu-
monia provides additional prognostic information beyond
conventional risk scoring. The majority of our patients were
in the non-risk group (PCIS480), whereas approximately
22.4% and 10.5% of the patients were classified into the risk
and high-risk groups, respectively. The risk and high-risk
groups showed decreased serum CGRP levels relative to the
non-risk group. To determine the cutoff score for CGRP
positivity, ROC analysis was conducted, and survival status
was evaluated. Serum samples with a score above the
determined cutoff value were was considered to have high
CGRP levels.
In summary, the present study indicated that serum CGRP
levels are potentially clinically useful as a prognostic
indicator after the onset of severe childhood pneumonia.
However, there are still several limitations of this study. First,
we could not determine CGRP levels in bronchoalveolar
lavage fluid (BALF) due to the difficulty in obtaining
samples. Second, we could not compare serum CGRP levels
in patients with severe pneumonia and in healthy controls.
More prospective clinical trials are needed to verify our
findings. Third, the association between serum CGRP levels
and mortality was not analyzed using a multivariate model
in this study. Further investigations in larger patient
populations are required to establish whether reduced CGRP
levels are an independent mortality risk factor for severe
pneumonia.
Highlights
1. CGRP was significantly increased in the survival group
than those in the non-survival group.
2. CGRP was highly expressed in non risk group compared
with risk and high risk groups.
3. Serum CGRP yielded AUC with a considerable sensitivity
and specificity.
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